SCHEMBL36537

SCHEMBL36537

CCC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 9/20 0.85
PGR P06401 8/20 0.85
USP2 O75604 7/20 0.85
CYP3A4 P08684 6/20 0.85
LMNA P02545 4/20 0.85
HIF1A Q16665 3/20 0.85
CNR1 P21554 3/20 0.85
CYP2C9 P11712 2/20 0.85
KDM4E B2RXH2 1/20 0.85
ALDH1A1 P00352 1/20 0.85
TDP1 Q9NUW8 1/20 0.85
NR1I2 O75469 3/20 0.49
MAPT P10636 2/20 0.49
MLNR O43193 1/20 0.49
ABCB11 O95342 1/20 0.49
CYP3A5 P20815 1/20 0.49
PPARG P37231 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11584724 1.00 NR3C1 (0.85) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11584722 1.00 NR3C1 (0.85) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL14339625 1.00 NR3C1 (0.85) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11584348 0.94 NR3C1 (0.75) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11584350 0.94 NR3C1 (0.75) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11584191 0.94 USP2 (0.85) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11584194 0.94 USP2 (0.85) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11586079 0.93 NR3C1 (0.74) NR3C1PGRUSP2CYP3A4LMNA
SCHEMBL11586080 0.93 NR3C1 (0.74) NR3C1PGRUSP2CYP3A4LMNA
Alclometasone Dipropionate SCHEMBL29459697 0.92 PGR (1.00) NR3C1PGRUSP2CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012051-A1 EXTERNAL PREPARATION KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-01-08 US claimed
US-20070287689-A1 Therapeutic And/Or Preventive Agents For Chronic Skin Diseases KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-12-13 US claimed
EP-1810692-A1 REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-07-25 EP claimed
US-6277834-B1 ADMINISTERING TO PATIENT A DOSAGE OF A SYNERGISTIC ADJUVANT PHOSPHODIESTER COMPOUND TO REDUCE NEEDED DOSAGE OF ADRENOCORTICAL HORMONE SENJU PHARMACEUTICAL CO. LTD. (JP) 2001-08-21 US claimed
EP-1086698-A1 AGENTS FOR RELIEVING SIDE EFFECTS OF ADRENAL CORTEX HORMONE Senju Pharmaceutical Co., Ltd. (JP) 2001-03-28 EP claimed
JP-8053354-A None JP disclosed
WO-2024133513-A1 COMPOSITION AND PRODUCTS COMPRISING AN ANTIBIOTIC AND A GLUCOCORTICOID FOR TREATING MASTITIS VIRBAC (FR) 2024-06-27 WO disclosed
WO-2024080311-A1 GENE INTRODUCTION METHOD, GENE THERAPY METHOD, AND TISSUE REGENERATION METHOD 栗田 昌和 2024-04-18 WO disclosed
WO-2024071398-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2024-04-04 WO disclosed
US-20240083899-A1 PURINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2024-03-14 US disclosed
US-11897885-B2 Purinone derivative hydrochloride ONO PHARMACEUTICAL CO., LTD. (JP) 2024-02-13 US disclosed
US-20240016818-A1 NOVEL USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF EPITHELIAL MICROBIAL INFECTIONS OF A FLUID CONTAINING ORGAN WITH A NATURAL EXTERIOR ORIFICE IN MAMMALS VIRBAC (FR) 2024-01-18 US disclosed
US-6432431-B1 GEL PATCHES CONTAINING CROTAMITON, CURING AGENTS, NONIONIC SURFACTANTS AND STEROLS ON NON-WOVEN FABRIC SUPPORTS HAVING AIR PERMEABILITY AND STORGE STABILITY; USED FOR ECZEMA, DERMATITIS AND ATOPIC DISEASES HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2002-08-13 US disclosed
US-6277834-B1 ADMINISTERING TO PATIENT A DOSAGE OF A SYNERGISTIC ADJUVANT PHOSPHODIESTER COMPOUND TO REDUCE NEEDED DOSAGE OF ADRENOCORTICAL HORMONE SENJU PHARMACEUTICAL CO. LTD. (JP) 2001-08-21 US disclosed
EP-1097712-A1 STEROID-CONTAINING CATAPLASMS AND PROCESS FOR PRODUCING THE SAME HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2001-05-09 EP disclosed
EP-1086698-A1 AGENTS FOR RELIEVING SIDE EFFECTS OF ADRENAL CORTEX HORMONE Senju Pharmaceutical Co., Ltd. (JP) 2001-03-28 EP disclosed
US-6207184-B1 PLASTER COMPRISING BACKING, ADHESIVE PASTE, COPOLYMER AND CROSSLINKING AGENT SSP CO., LTD. (JP) 2001-03-27 US disclosed
EP-1077066-A1 PREVENTIVES/REMEDIES FOR SKIN DISEASES Showa Denko Kabushiki Kaisha (JP) 2001-02-21 EP disclosed
EP-0965626-A1 Hydrophilic adhesive masses SSP Co., Ltd. (JP) 1999-12-22 EP disclosed
JP-H0853354-A AQUEOUS PLASTER FOR DERMATOSIS HISAMITSU PHARMACEUT CO INC 1996-02-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897885-B2 Purinone derivative hydrochloride BTK, P2RY1, P2RY13 NR3C1 1906/4885PGR 599/4885USP2 3695/4885
US-20090012051-A1 EXTERNAL PREPARATION CYP4A11, CYP46A1, CYP11B2 NR3C1 556/4885PGR 2297/4885USP2 2116/4885
US-20070287689-A1 Therapeutic And/Or Preventive Agents For Chronic Skin Diseases PDE4A, PDE3B, PDE2A NR3C1 62/4885PGR 1575/4885USP2 2609/4885
US-20240083899-A1 PURINONE DERIVATIVE BTK, KIT, SYK NR3C1 1166/4885PGR 634/4885USP2 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.